🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

Syndax Pharmaceuticals clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our UK, USA and China registers with Syndax Pharmaceuticals as lead sponsor. Synced 26 Sep 2026
5Current trials
3Recruiting now
3Drugs in these trials
3Trial registers
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

Syndax Pharmaceuticals is the lead sponsor of 5 current clinical trials in our UK, USA and China registers. 3 are recruiting patients now. The most common phase is Phase 2. The drugs named most often in its trials are Revumenib, Axatilimab and Cobicistat. The most-studied condition is Acute Myeloid Leukemias.

ClinicalTrials.gov trials by status

  • Recruiting360%
  • Active, closed240%

Trials by phase

  • Phase 2240%
  • Phase 1120%
  • Phase 3120%
  • Phase 1/2120%
01

Clinical trials sponsored by Syndax Pharmaceuticals

5 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
NCT04065399 · Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Mixed Lineage Acute Leukemia
Phase 1/2 Recruiting 2019-11 USA
Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation
NCT07211958 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemias
Drug: Revumenib
Phase 3 Recruiting 2025-11 UK, USA
A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD)
NCT04710576 · ClinicalTrials.gov ↗ · Chronic Graft-versus-host-disease
Phase 2 Recruiting 2021-03 UK, USA, China
MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF)
NCT06132256 · ClinicalTrials.gov ↗ · Idiopathic Pulmonary Fibrosis
Phase 2 Active, closed 2023-12 UK, China
A Study of Revumenib in Combination With Intensive Chemotherapy in Participants With Acute Myeloid Leukemias
NCT06226571 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemias
Drug: Revumenib
Phase 1 Active, closed 2024-05 UK, USA

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in Syndax Pharmaceuticals trials

3 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in Syndax Pharmaceuticals trials

7 conditions
Acute Myeloid Leukemias2Idiopathic Pulmonary Fibrosis1Chronic Graft-versus-host-disease1Acute Myeloid Leukemia1Acute Lymphoblastic Leukemia1Mixed Lineage Acute Leukemia1Mixed Phenotype Acute Leukemia1
04

By trial register

RegisterTrialsRecruiting
Clinical trials in UK42
Clinical trials in USA43
Clinical trials in China21

A trial with sites in more than one country appears in each of those registers.

05

Questions about Syndax Pharmaceuticals trials

How many clinical trials does Syndax Pharmaceuticals sponsor?

Syndax Pharmaceuticals is the lead sponsor of 5 current trials on ClinicalTrials.gov in our UK, USA and China registers, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Syndax Pharmaceuticals trials recruiting?

Yes. 3 of its 5 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Syndax Pharmaceuticals testing?

Its current trials name 3 drugs and biologicals as interventions. The most frequent are Revumenib (3), Axatilimab (2) and Cobicistat (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.